Therapeutic Drug Monitoring in Uncontrolled Arterial Hypertension: Result of the Pilot Part of Study

Abstract

INTRODUCTION: Despite the recently established evidence-based and systemic approach to treatment for arterial hypertension (AH), not in all cases its control can be achieved.

AIM: To conduct a comparative analysis of the concentration of antihypertensive drugs (AHTDs) in blood serum of patients with controlled and uncontrolled AH.

MATERIALS AND METHODS: Fifty six patients were included. Inclusion criteria: age ≥ 18 years, signing of informed consent, established diagnosis of AH, regular intake of any two of study antihypertensive drugs (lisinopril, amlodipine, valsartan) and also of indapamide at stable doses, for women — adequate contraception. According to the results of daily monitoring of the arterial pressure (AP), patients were divided into two groups: the first group — controlled hypertension (AP < 140/90 mmHg; n = 39), the second — uncontrolled hypertension (AP ≥ 140/90 mmHg; n = 17). The mean age of patients in the first group was 65.03 ± 10.80 years, in the second — 63.50 ± 8.31 (p = 0.576). In the first group, women prevailed (64.1% vs. 35.3%, p = 0.047) and the mean body mass index was lower (26.30 ± 1.38 kg/m² vs. 32.20 ± 4.15 kg/m², p = 0.02). In patients of both groups, venous blood was taken in fasting condition in the morning and 2 hours after intake of AHTDs to assess their concentration by high-performance liquid chromatography. The analytical range for lisinopril, indapamide, amlodipine was 5–500 ng/ml, for valsartan — 10–10,000 ng/ml.

RESULTS: In the first group, equilibrium concentration of lisinopril was 2.67 times higher (p = 0.053), and concentration of indapamide in 2 hours after intake was 1.83 times higher (р = 0,084); when normalized to the dose, the differences were leveled out (p > 0.05). Concentrations of amlodipine and valsartan did not differ between the groups both before and 2 hours after intake (p > 0.05). In 3 of 39 (7.7%) patients with controlled hypertension and in one of 17 patients (5.9%, p = 1.0) with uncontrolled hypertension, AHTDs were detected in blood serum, which were not administered to them.

CONCLUSIONS: Results of the pilot part of the study (n = 56) demonstrated the absence of difference between the mean concentrations of the study AHTDs in the blood serum of patients with controlled and uncontrolled AH, and in some cases the presence of traces of AHTDs not administered by the doctor.

References

[1] Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population- based studies from 90 countries. Circulation. 2016;134(6):441–50. doi: 10.1161/CIRCULATIONAHA.115.018912

[2] Mills K.T., Bundy J.D., Kelly T.N., et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries // Circulation. 2016. Vol. 134, No. 6. Р. 441–450. doi: 10.1161/CIRCULATIONAHA.115.018912

[3] Balanova YuA, Shalnova SA, Imaeva AE, et al. Prevalence, Awareness, Treatment and Control of Hypertension in Russian Federation (Data of Observational ESSERF-2 Study). Rational Pharmacotherapy in Cardiology. 2019;15(4):450–66. (In Russ). doi: 10.20996/1819-6446-2019-15-4-450-466

[4] Баланова Ю.А., Шальнова С.А., Имаева А.Э., и др. Распространенность артериальной гипертонии, охват лечением и его эффективность в Российской Федерации (данные наблюдательного исследования ЭССЕ-РФ-2) // Рациональная Фармакотерапия в Кардиологии. 2019. Т. 15, № 4. С. 450–466. doi: 10.20996/1819-6446-2019-15-4-450-466

[5] Barsukov AV, Korneychuk NN, Shustov SB. Нigh-renin hypertensions: from symptom to diagnosis. Herald of the Northwestern State Medical University named after I.I. Mechnikov. 2017;9(2):7–18. (In Russ).

[6] Барсуков А.В., Корнейчук Н.Н., Шустов С.Б. Высокорениновые артериальные гипертензии: от симптома к диагнозу // Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2017. Т. 9, № 2. С. 7–18.

[7] Gusakova EA, Gorodetskaya IV. The restriction of sympathoadrenal system activity and the body’s resistance to stress. Vestnik VGMU. 2020;19(6):41–53. (In Russ). doi: 10.22263/2312-4156.2020.6.41

[8] Гусакова Е.А., Городецкая И.В. Ограничение активности симпатоадреналовой системы и устойчивость организма к стрессу // Вестник Витебского государственного медицинского университета. 2020. Т. 19, № 6. С. 41–53. doi: 10.22263/2312-4156.2020.6.41

[9] Popov VV, Bulanova NA, Ivanov GG. Current target of antihypertensive therapy. Data from clinical trials. Part 1. Rational Pharmacotherapy in Cardiology. 2012;8(1):88–94. (In Russ). doi: 10.20996/1819-6446-2012-8-1-88-94

[10] Попов В.В., Буланова Н.А., Иванов Г.Г. Современные мишени антигипертензивной терапии. Данные клинических исследований. Часть 1 // Рациональная фармакотерапия в кардиологии. 2012. Т. 8, № 1. С. 88–94. doi: 10.20996/1819-6446-2012-8-1-88-94

[11] Peeters LEJ, Feyz L, Boersma E, et al. Clinical Applicability of Monitoring Antihypertensive Drug Levels in Blood. Hypertension. 2020;76(1):80–6. doi: 10.1161/HYPERTENSIONAHA.120.15038

[12] Peeters L.E.J., Feyz L., Boersma E., et al. Clinical Applicability of Monitoring Antihypertensive Drug Levels in Blood // Hypertension. 2020. Vol. 76, No. 1. Р. 80–86. doi: 10.1161/HYPERTENSIONAHA.120.15038

[13] Myl’nikov PYu, Tranova Yu, Shchul’kin AV, et al. Development and Validation of HPLC-MS/MS Method for Quantitative Determination of Metoprolol in Blood Plasma of Patients. Nauka Molodykh (Eruditio Juvenium). 2022;10(4):361–72. (In Russ). doi: 10.23888/HMJ2022 104361-372

[14] Мыльников П.Ю., Транова Ю., Щулькин А.В., и др. Разработка и валидация методики количественного определения метопролола в плазме крови пациентов методом ВЭЖХ-МС/МС // Наука молодых (Eruditio Juvenium). 2022. Т. 10, № 4. С. 361–372. doi: 10.23888/HMJ2022104361-372

[15] Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation, and Management: a Scientific Statement from the American Heart Association. Hypertension. 2018;72(5):e53–e90. doi: 10.1161/hyp.0000000000000084

[16] Carey R.M., Calhoun D.A., Bakris G.L., et al. Resistant Hypertension: Detection, Evaluation, and Management: a Scientific Statement from the American Heart Association // Hypertension. 2018. Vol. 72, No. 5. P. e53–e90. doi: 10.1161/hyp.0000000000000084

[17] Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–8. doi: 10.1093/eurheartj/eht295

[18] Chowdhury R., Khan H., Heydon E., et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences // European Heart Journal. 2013. Vol. 34, No. 38. P. 2940–2948. doi: 10.1093/eurheartj/eht295

[19] Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–42. doi: 10.1161/CIRCULATIONAHA.111.068064

[20] Daugherty S.L., Powers J.D., Magid D.J., et al. Incidence and prognosis of resistant hypertension in hypertensive patients // Circulation. 2012. Vol. 125, No. 13. P. 1635–1642. doi: 10.1161/CIRCULATIONAHA.111.068064

[21] Vrijens B, Antoniou S, Burnier M, et al. Current Situation of Medication Adherence in Hypertension. Front Pharmacol. 2017;8:100. doi: 10.3389/fphar.2017.00100

[22] Vrijens B., Antoniou S., Burnier M., et al. Current Situation of Medication Adherence in Hypertension // Frontiers in Pharmacology. 2017. Vol. 8. P. 100. doi: 10.3389/fphar.2017.00100

[23] Kartashova ESh, Batishcheva GA, Zhdanova OA, et al. Pharmacoepidemiology of the administration of antihypertensive drugs by doctors in the Voronezh region in comparison with the results of the PYTHAGOR IV study. I. P. Pavlov Russian Medical Biological Herald. 2021;29(4):475–82. (In Russ). doi: 10.17816/PAVLOVJ64271

[24] Карташова Э.Ш., Батищева Г.А., Жданова О.А., и др. Фармакоэпидемиология назначений антигипертензивных препаратов врачами Воронежской области в сравнении с результатами исследования ПИФАГОР IV // Российский медико-биологический вестник имени академика И. П. Павлова. 2021. Т. 29, № 4. С. 475–482. doi: 10.17816/PAVLOVJ64271

RIGHTS & PERMISSIONS

Seleznev S.V., Yаkushin S.S., Mylnikov P.Y., Tranova Y.S., Shchul'kin A.V., Yakusheva E.N., Nikulina N.N.